The liver-X-receptors have shown anti-inflammatory ability in several animal models of respiratory disease. Our purpose is to investigate the effect of LXR ligand in allergen-induced airway remodeling in mice. Ovalbumin-sensitized mice were chronically challenged with aerosolized ovalbumin for 8 weeks. Some mice were administered a LXR agonist, T0901317 (12.5, 25, 50 mg/kg bodyweight) before challenge. Then mice were evaluated for airway inflammation, airway hyperresponsiveness and airway remodeling. T0901317 failed to attenuate the inflammatory cells and Th2 cytokines in bronchoalveolar lavage fluid. But the application of T0901317 reduced the thickness of airway smooth muscle and the collagen deposition. Meanwhile, T0901317 treatment evidently abolished the high level of OVA-specific IgE, TGF-β1 and MMP-9 in lung. So LXRs may attenuate the progressing of airway remodeling, providing a potential treatment of asthma.
References
[1]
Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383: 728–731. doi: 10.1038/383728a0
[2]
Costet P, Luo Y, Wang N, Tall AR (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275: 28240–28245.
[3]
Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, et al. (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 97: 12097–12102. doi: 10.1073/pnas.200367697
[4]
Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors: Nat Med. 9: 213–219. doi: 10.1038/nm820
[5]
Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P (2003) Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278: 10443–10449. doi: 10.1074/jbc.m213071200
[6]
Benayoun L, Pretolani M (2003) Airway remodeling in asthma: mechanisms and therapeutic perspectives. Med Sci 19: 319–326.
[7]
Solan PD, Piraino G, Hake PW, Denenberg A, O'Connor M, et al. (2011) Liver X receptor α activation with the synthetic ligand T0901317 reduces lung injury and inflammation after hemorrhage and resuscitation via inhibition of the nuclear factor κB pathway. 35: 367–374. doi: 10.1097/shk.0b013e3181f7d742
[8]
Crisafulli C, Mazzon E, Paterniti I, Galuppo M, Bramanti P, et al. (2010) Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respir Res 22: 11–19. doi: 10.1186/1465-9921-11-19
[9]
Smoak K, Madenspacher J, Jeyaseelan S, Williams B, Dixon D, et al. (2008) Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense:J Immunol. 180: 3305–3312. doi: 10.4049/jimmunol.180.5.3305
[10]
Wang D, Liu M, Wang Y, Luo M, Wang J, et al. (2011) Synthetic LXR agonist T0901317 attenuates lipopolysaccharide-induced acute lung injury in rats. Int Immunopharmacol 11: 2098–2103. doi: 10.1016/j.intimp.2011.09.002
[11]
Delvecchio CJ, Bilan P, Radford K, Stephen J, Trigatti BL, et al. (2007) Liver X receptor stimulates cholesterol efflux and inhibits expression of proinflammatory mediators in human airway smooth muscle cells. Mol Endocrinol 21: 1324–1334. doi: 10.1210/me.2007-0017
[12]
Blaschke F, Leppanen O, Takata Y, Caglayan E, Liu J, et al. (2004) Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 95: 110–123. doi: 10.1161/01.res.0000150368.56660.4f
[13]
Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, et al. (2003) Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 120: 246–255. doi: 10.1046/j.1523-1747.2003.12033.x
[14]
Tagaya E, Tamaoki J (2007) Mechanisms of airway remodeling in asthma. Allergol Int 56: 331–340. doi: 10.2332/allergolint.r-07-152
[15]
Warner SM, Knight DA (2008) Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 8: 44–48. doi: 10.1097/aci.0b013e3282f3b5cb
[16]
Park MC, Kwon YJ, Chung SJ, Park YB, Lee SK (2010) Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology 49: 882–890. doi: 10.1093/rheumatology/keq007
[17]
Hamelmann E, Tadeda K, Oshiba A, Gelfand EW (1999) Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness—a murine model. Allergy 54: 297–305. doi: 10.1034/j.1398-9995.1999.00085.x
[18]
Heine G, Dahten A, Hilt K, Ernst D, Milovanovic M, et al. (2009) Liver X receptors control IgE expression in B cells. J Immunol 182: 5276–5282. doi: 10.4049/jimmunol.0801804
[19]
Nunomura S, Endo K, Makishima M, Ra C (2010) Oxysterol represses high-affinity IgE receptor-stimulated mast cell activation in Liver X receptor-dependent and -independent manners. FEBS Lett 584: 1143–1148. doi: 10.1016/j.febslet.2010.02.006
[20]
Brusselle GG, Kips JC, Tavernier JH, van der Heyden JG, Cuvelier CA, et al. (1994) Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 24: 73–80. doi: 10.1111/j.1365-2222.1994.tb00920.x
[21]
Walter DM, McIntire JJ, Berry G, McKenzie ANJ, Donaldson DD, et al. (2001) Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity. J Immunol 167: 4668–4675. doi: 10.4049/jimmunol.167.8.4668
[22]
Makinde T, Murphy RF, Agrawal DK (2007) The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol 85: 348–356. doi: 10.1038/sj.icb.7100044
[23]
Brown SD, Baxter KM, Stephenson ST, Esper AM, Brown LA, et al. (2012) Airway TGF-β1 and oxidant stress in children with severe asthma: association with airflow limitation. J Allergy Clin Immunol 129: 388–396. doi: 10.1016/j.jaci.2011.11.037
[24]
Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, et al. (1997) Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med 156: 591–599. doi: 10.1164/ajrccm.156.2.9609066
[25]
Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207–214. doi: 10.1038/nrm763
[26]
Lee YC, Song CH, Lee HB, Oh JL, Rhee YK, et al. (2001) A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J Allergy Clin Immunol 108: 1021–1026. doi: 10.1067/mai.2001.120132
[27]
Birrell MA, De Alba J, Catley MC, Hardaker E, Wong S, et al. (2008) Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol 181: 4265–4271. doi: 10.4049/jimmunol.181.6.4265
[28]
Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, et al. (2004) T0901317 is a dual LXR/FXR agonist. Mol Genet Metab 83: 184–187. doi: 10.1016/j.ymgme.2004.07.007
[29]
Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D (2007) Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27: 2606–2611. doi: 10.1161/atvbaha.107.152694
[30]
Louis R, Schleich F, Barnes PJ (2012) Corticosteroids: still at the frontline in asthma treatment? Clin Chest Med 33: 531–541. doi: 10.1016/j.ccm.2012.05.004
